WELLESLEY HILLS, Mass., Nov. 2 /PRNewswire-FirstCall/ -- MacroChem will present at the Rodman & Renshaw 8th Annual Healthcare Conference on Wednesday, November 8th, 2006 at 2:30PM ET at the Palace Hotel in New York. The Conference, which includes presentations by over 300 companies, as well as experts from the medical, scientific and investment communities, will be attended by investors, venture capitalists, company executives, scientists and other industry leaders.
Robert J. DeLuccia, President and CEO of MacroChem, will provide a company overview, including discussion about MacroChem’s lead product, EcoNail(TM), which is currently undergoing Phase II trials.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our patented enhancer, SEPA(R): EcoNail, to treat fungal infection of the nail and Opterone(R), to treat male hypogonadism. In addition to our SEPA technology, we are also evaluating applications for MacroDerm(TM), our patented series of polymers that impede penetration of active ingredients through the skin. For more information visit our website, http://www.macrochem.com.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled “Risk Factors” in MacroChem’s Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.
Contact: MacroChem Corp.: Bernard Patriacca - VP/CFO (781) 489-7310 Investor Relations: The Investor Relations Group, Inc. Jordan Silverstein/Christine Berni (212) 825-3210
MacroChem Corporation
CONTACT: Bernard Patriacca, VP/CFO of MacroChem, +1-781-489-7310; orJordan Silverstein or Christine Berni of The Investor Relations Group, Inc.for MacroChem, +1-212-825-3210
Web site: http://www.macrochem.com//
